ID   KFr13
AC   CVCL_V534
SY   KFr
DR   CGH-DB; 327-2
DR   CGH-DB; 349-3
DR   Wikidata; Q54899827
RX   PubMed=3467111;
RX   PubMed=10741911;
RX   PubMed=11185891;
RX   PubMed=17671176;
RX   PubMed=18319717;
RX   PubMed=18483383;
CC   Population: Japanese.
CC   Doubling time: 24.8 hours (Note=In presence of 0.5 mug cisplatin/ml), 27.2 hours (Note=In presence of 1 mug cisplatin/ml) (PubMed=3467111).
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_V533 ! KF28
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 9
CH   CVCL_V535 ! KFr13Tx
//
RX   PubMed=18319717; DOI=10.1038/sj.bjc.6604279; PMCID=PMC2275483;
RA   Goto, Tomoko
RA   Takano, Masashi
RA   Hirata, Junko
RA   Tsuda, Hitoshi
RT   "The involvement of FOXO1 in cytotoxic stress and drug-resistance
RT   induced by paclitaxel in ovarian cancers.";
RL   Br. J. Cancer 98:1068-1075(2008).
//
RX   PubMed=18483383; DOI=10.1158/1078-0432.CCR-07-4358;
RA   Ishibashi, Masako
RA   Nakayama, Kentaro
RA   Yeasmin, Shamima
RA   Katagiri, Atsuko
RA   Iida, Kouji
RA   Nakayama, Naomi
RA   Fukumoto, Manabu
RA   Miyazaki, Kohji
RT   "A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a
RT   potential target for taxol resistance in ovarian cancer.";
RL   Clin. Cancer Res. 14:3149-3155(2008).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi, Ryoko
RA   Tsuda, Hitoshi
RA   Kanai, Yae
RA   Kasamatsu, Takahiro
RA   Sengoku, Kazuo
RA   Hirohashi, Setsuo
RA   Inazawa, Johji
RA   Imoto, Issei
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=3467111; DOI=10.1093/jnci/77.6.1181;
RA   Kikuchi, Yoshihiro
RA   Miyauchi, Munenori
RA   Kizawa, Isao
RA   Oomori, Keibun
RA   Kato, Koichi
RT   "Establishment of a cisplatin-resistant human ovarian cancer cell
RT   line.";
RL   J. Natl. Cancer Inst. 77:1181-1185(1986).
//
RX   PubMed=10741911; DOI=10.1007/s004320050027;
RA   Yamamoto, Kenji
RA   Kikuchi, Yoshihiro
RA   Kudoh, Kazuya
RA   Nagata, Ichiro
RT   "Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive
RT   and -resistant human ovarian carcinoma cell lines.";
RL   J. Cancer Res. Clin. Oncol. 126:168-172(2000).
//
RX   PubMed=11185891; DOI=10.1093/jjco/hyd116;
RA   Yamamoto, Kenji
RA   Kikuchi, Yoshihiro
RA   Kudoh, Kazuya
RA   Hirata, Junko
RA   Kita, Tsunekazu
RA   Nagata, Ichiro
RT   "Treatment with paclitaxel alone rather than combination with
RT   paclitaxel and cisplatin may be selective for cisplatin-resistant
RT   ovarian carcinoma.";
RL   Jpn. J. Clin. Oncol. 30:446-449(2000).
//